Koers Luoxin Pharmaceuticals Group Stock Co., Ltd.
Aandelen
002793
CNE1000026S7
Farmaceutische producten
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
4,63 CNY | +2,89% | +7,18% | -13,62% |
Omzet 2022 | 3,59 mld. 495 mln. 460 mln. | Omzet 2023 | 2,36 mld. 326 mln. 303 mln. | Marktkapitalisatie | 5,83 mld. 805 mln. 748 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -1,23 mld. -169 mln. -157 mln. | Nettowinst (verlies) 2023 | -661 mln. -91,29 mln. -84,84 mln. | EV/omzet 2022 | 2,93 x |
Nettoschuld 2022 | 2,17 mld. 300 mln. 279 mln. | Nettoschuld 2023 | 798 mln. 110 mln. 102 mln. | EV/omzet 2023 | 2,8 x |
K/w-verhouding 2022 |
-8,92
x | K/w-verhouding 2023 |
-8,79
x | Werknemers | 4.582 |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 55,27% |
1 dag | +2,89% | ||
1 week | +7,18% | ||
1 maand | +1,98% | ||
3 maanden | +11,57% | ||
6 maanden | -18,05% | ||
Lopend jaar | -13,62% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Zhen Teng Liu
CEO | Chief Executive Officer | 38 | 23-04-20 |
Xian Chen
DFI | Director of Finance/CFO | 41 | 08-07-21 |
Hong Yan Liu
BRD | Director/Board Member | 42 | 31-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Feng Sheng Han
SEC | Corporate Secretary | 49 | 23-04-20 |
Liang Wei Song
CHM | Chairman | 44 | 31-01-23 |
Yun Pei Guo
BRD | Director/Board Member | 76 | 19-05-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 34 M€ | +2,67% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
30-04-24 | 4,63 | +2,89% | 15 852 700 |
29-04-24 | 4,5 | +4,17% | 13 606 400 |
26-04-24 | 4,32 | -0,46% | 8 492 532 |
25-04-24 | 4,34 | +3,09% | 18 942 610 |
slotkoers Shenzhen S.E., 30 april 2024
Meer koersenVaira. 1 jan. | Kapi. | |
---|---|---|
-13,62% | 696 mln. | |
+26,08% | 662 mld. | |
+21,85% | 546 mld. | |
-4,77% | 359 mld. | |
+16,97% | 323 mld. | |
+5,69% | 290 mld. | |
+13,68% | 234 mld. | |
+3,65% | 198 mld. | |
-11,12% | 194 mld. | |
-3,40% | 157 mld. |